CTO DUO
Cervicothoracic zone concept, developed for the transition between neck and upper back.
Formulated for the cervicothoracic junction, a region of dense peripheral innervation and frequent clinical attention.
Label QR
Opens the public information page in the reader's language.
https://www.siriamlab.com/qr/cto-duo
Open patient pageEssential reading. The complete scientific monograph is one click away.
Chapter 01
Product identity
Identification, classification, family, intended use, anatomical region and the documents this record is governed by.
Identification of the record: product identifier, classification, family, intended use, anatomical region and the controlled documents it is governed by.
Documentation metadata+
Chapter 01 — related anatomy
Related documents
Future references
- GTIN / label identifierReservedCommercial identifier reserved for the published label.
Record identification
- Product ID
- SIR-CTO-01
- Family
- CTO DUO
- Region
- Cervical — cervicothoracic junction
- Last update
- 2026-01
Handbook source
Neurovascular and afferent modulation of the cervicothoracic transition (C8–T4), EMG targeted.
- Phase 1: activation and circulation
- Phase 2: stabilisation and integration
- Developer
- MT DO, DCP
- Pharmacist
- AVA
- Chapter version
- 1.0
- Product ID
- SIR-CTO-01
The handbook is the scientific master. Every statement rendered on this record originates from this chapter; the platform never creates independent scientific content.
Chapter 02
Executive summary
The record in short: professional summary, patient summary and the sequential treatment model behind it.
The record read in short: professional summary, patient summary and the sequential treatment model behind the formulation.
Documentation metadata+
Chapter 02 — related anatomy
Declared; content in preparation.
Related documents
Future references
- TranslationsReservedExecutive summary in Dutch, French and German.
Executive summary
The reading entry of the record: what the composition is for, in professional and in patient language.
Purpose
CTO DUO addresses the cervicothoracic transition as a single continuous surface field rather than as two separate areas.
Clinical goal
Primary anatomical region
neck
Primary therapeutic objective
Documented cutaneous topical composition for the cervicothoracic transition field.
Professional summary
CTO DUO is documented as a cutaneous topical composition for the neck application field. This summary is maintained by the documentation team and updated with each revision of the record.
Patient summary
Cervicothoracic zone concept, developed for the transition between neck and upper back.
Keywords
Chapter 03
Anatomy snapshot
The anatomical region of the record and every structure of its application field, resolving into the Neuro Atlas.
The anatomical identity of the record: the region, the segmental levels and the surface territory the formulation is documented for.
Documentation metadata+
Chapter 03 — related anatomy
Related documents
Future references
- 3D Atlas referenceReservedVolumetric reference of the field, prepared for the atlas engine.
- EMG referenceReservedFunctional EMG dataset linked to the segmental levels of this record.
- SRST referenceReservedSegmental reflex surface topography mapping.
Snapshot
Anatomy snapshot
Six metameric expressions per segment — dermatome, myotome, sclerotome, viscerotome, micro-angiotome and neurotome. Individual structures inside an expression open their own illustration plate.
Anatomical identity
Primary region
Dermatomes
Peripheral nerves
Plexus
Metamers
Neurocutaneous territories
Body regions
Surface anatomy
- 3D Atlas referenceReservedVolumetric field reference.
- EMG referenceReservedFunctional EMG dataset.
- SRST referenceReservedSegmental reflex surface topography.
Chapter 04
Clinical purpose
Objective, strategy, workflow and the boundaries within which this record is documented.
The clinical objective of the record, its rationale, and the boundaries within which it is documented.
Documentation metadata+
Chapter 04 — related anatomy
Related documents
Future references
- Evidence levelReservedGraded evidence classification per documented statement.
- Clinical casesReservedStructured practitioner observations linked to this record.
Purpose
Why this formulation exists
CTO DUO is documented as a cutaneous topical composition for the neck application field. This summary is maintained by the documentation team and updated with each revision of the record.
Why this record exists
CTO DUO addresses the cervicothoracic transition as a single continuous surface field rather than as two separate areas.
Neurocutaneous region it was designed for
Cervicothoracic neurocutaneous zone
Anatomical interface it addresses
Cervical and cervicothoracic transition, including the supraclavicular field of the brachial plexus.
Clinical philosophy
At the cervicothoracic junction, supraclavicular branches of the cervical plexus meet the upper thoracic segmental bands and the medial branches of the dorsal rami, producing one of the densest superficial innervation patterns of the trunk.
- Cutaneous topical composition; the application field is defined by the treating professional.
- Application is documented per session so routines remain comparable over time.
Chapter 05
Application protocol
Timeline, application sites, professional and patient instructions, safety and storage.
Phases, cadence, duration, zone order and the documented application sequence, with practitioner and patient notes.
Documentation metadata+
Chapter 05 — related anatomy
Related documents
Future references
- Printable protocolReservedPrint-ready protocol sheet generated from this record.
Surface
Application zones
The zones listed are possible application locations. The practitioner identifies the exact spot within these possibilities using the SRST (Segmental Reflex Sensitisation Test). Future evaluation will use EMG before and after application.
Cervicothoracic junction
Detailed application guidance is in preparation.
Application fieldUpper trapezius field
Detailed application guidance is in preparation.
Application fieldInterscapular border
Detailed application guidance is in preparation.
Application field
Protocol
Application protocol
Phase 1
Release
Week 1–2 · 1–2 applications per day
Until phase 2 is introduced
The first texture is applied thinly on the target zone within the possible application zones, following the documented zone order.
Cervicothoracic junctionUpper trapezius fieldInterscapular borderPhase 2
Integration
Week 3 evening · from week 4 morning and evening
Until the product is finished
From week 3 phase 2 is added in the evening: phase 1 in the morning on the target zone, phase 2 in the evening on that same target zone. From week 4 — or once phase 1 is finished and phase 2 is recommended by the therapist — phase 2 is applied morning and evening on the target zone until the product is finished.
Cervicothoracic junctionUpper trapezius fieldInterscapular borderMaintenance
Continued routine
1–3 sessions per week
Ongoing, reviewed periodically
The routine is continued at a reduced cadence and reviewed with the practitioner at agreed intervals. Observations stay in the professional log so successive periods remain comparable.
Cervicothoracic junctionUpper trapezius fieldInterscapular border
Zone sequence
- 01Cervicothoracic junction
- 02Upper trapezius field
- 03Interscapular border
- 01Apply step one along the trapezius ridge toward the interscapular border.
- 02Allow the first layer to settle.
- 03Apply step two across the same field.
Landmarks
C7 spinous process and the acromion define the field.
Coverage
Even, thin coverage from midline to the scapular border.
Review
Reviewed with the practitioner at agreed intervals.
CTO protocol (definitive)
Zones
- Subclavicular left / right
- Sternum (T2–T4)
- Parascapular dorsal
Week 1–2
CTO-1 (1–2× per day)
Week 3
Morning: CTO-2 · Evening: CTO-1
Week 4
CTO-2 (1–2× per day)
Week 5
CTO-2 (evening)
On relapse: CTO-1 for 3 days.
Chapter 06
Formulation science
The scientific philosophy of the composition: sequential formulation, phase relationship and ingredient rationale.
The composition read as an architecture, with the current formula held read-only and any proposed successor documented alongside it.
Documentation metadata+
Chapter 06 — related anatomy
Declared; content in preparation.
Related documents
Future references
- Ingredient linksReservedEvery constituent resolving to its RM-001 entry.
- Version comparisonReservedSide-by-side comparison of current and proposed composition.
Composition
Formulation architecture
The composition is documented as a map rather than a list. Every constituent is recorded with the function it carries, the reason it is present in this field, how it relates to the rest of the composition and the cutaneous topical formulation category it belongs to.
- 01Aqua base
Aqua
Carrier system
- Functional role
- Carrier phase
- Formulation purpose
- Sets the water phase that determines spreadability across a defined surface field.
- Interaction within the composition
- Holds the humectant fraction in solution and carries the emulsified lipid phase evenly over the zone.
- 02Glycerin
Glycerin
Humectant
- Functional role
- Moisture binding
- Formulation purpose
- Keeps the applied layer supple so the same field can be worked repeatedly without dryness on the skin surface.
- Interaction within the composition
- Balances the emollient fraction: the humectant governs the water phase, the emollient the lipid phase.
- 03Shea butter
Butyrospermum parkii butter
Emollient
- Functional role
- Skin-feel and occlusive body
- Formulation purpose
- Gives the texture enough body to stay on the applied zone rather than running along the hairline.
- Interaction within the composition
- Carries the lipid-soluble antioxidant fraction and slows the evaporation of the water phase.
- 04Panthenol
Panthenol
Conditioning agent
- Functional role
- Surface conditioning
- Formulation purpose
- Documented as a conditioning constituent of the cutaneous topical base; contributes to a smooth, non-tacky finish.
- Interaction within the composition
- Water-soluble; works alongside glycerin in the same phase without altering the emulsion.
- 05Tocopherol
Tocopherol
Antioxidant stabiliser
- Functional role
- Formulation stability
- Formulation purpose
- Protects the lipid fraction over the shelf life of the record so successive batches stay comparable.
- Interaction within the composition
- Dissolved in the shea fraction; stabilises the constituents it is dispersed in rather than acting on the skin.
Reading the map
Constituents are grouped by formulation category: a carrier system that governs spread, a water phase that governs feel, a lipid phase that governs stay-time, and stabilising constituents that keep successive batches comparable. Interactions describe the composition only; no physiological effect is asserted.
Cutaneous topical formulation rationale
The formulation is built for reproducible application on the documented zones: a texture that spreads thinly, a controlled sensory profile and a composition suitable for repeated professional use.
Representative composition overview. The full INCI listing is published in the composition index.
Chapter 07
QR patient information
The label surface, generated from the digital record: what the formulation is, its timeline, application areas, safety and quality assurance.
The label surface of the record, generated from the digital record so patient information can never drift from the documentation.
Documentation metadata+
Chapter 07 — related anatomy
Related documents
Future references
- Printed QRReservedProduction-ready QR code bound to the published version.
Documentation
Downloads
Label
QR resources
Each package carries a QR code that resolves to this documentation record in the reader's language, together with the composition index and the current application protocol. Codes are versioned, so updated documentation reaches practitioners without relabelling.
Resolves to /products/cto-duo
QR information
- Current QR resolves to
- /products/cto-duo
- Current version
- 1.4
- Last update
- 2026-01
- Batch number
- CTO-2601
Storage information
Store closed, upright and away from direct sunlight. Storage conditions are documented on the label and repeated here without alteration.
Professional information
Professional reading opens the complete monograph: anatomy, composition architecture, protocol and revision record.
Patient information
Essential reading describes what the composition is, where it is applied and in which order, without clinical interpretation.
- Multilingual QR contentReservedReserved: Dutch, English, French and German resolution of the same record.
Quality system
Version control
The current composition and any proposed successor are documented side by side. Approval and change control are handled outside the platform.
Current formula
- Version
- 1.4
- Revision date
- 2026-01
Current approved composition.
Proposed formula
No successor is currently proposed for this record.
QR information
- QR target
- /products/cto-duo
- Batch reference
- CTO-2601
- Record status
- Documented
The QR code printed on the label resolves to this record. The product page is the single source of truth; printed material never carries content that is not documented here.
Controlled documents →Continue
Explore further
Cutaneous topical formulation. Information is provided for education and professional reference; it is not medical advice and implies no therapeutic effect.
Back to the ecosystem →